Skip to main content

Zivo Bioscience, Inc.

corporate_fare Company Profile

Zivo Bioscience, Inc.

ZIVO·OTC·Healthcare·CIK 0001101026

Zivo Bioscience, Inc. is a research and development company operating in the biotech and agtech sectors. The company's intellectual property portfolio includes proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Zivo Bioscience focuses on its proprietary algal culture and materials derived from it, which are believed to offer benefits for animal and human health, primarily through inflammation-modulating and immune-boosting properties. The company's efforts are centered on two main initiatives. The first involves identifying bioactive extracts or novel bioactive molecules from its proprietary algal culture to treat various diseases. The second initiative focuses on utilizing the proprietary algal culture in its whole form as a food product to leverage its nutritional value. In the first quarter of 2022, Zivo Bioscience reformulated its biotech and agtech businesses around these two concepts, developing a focused strategy for each business after reviewing market potential, scale, profit, and associated technical and business risks.

Zivo Bioscience, Inc. (OTC:ZIVO) is a publicly traded company in the Healthcare sector. Wiseek monitors ZIVO SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • 10% Owner Mark Strome Buys $200K in Zivo Bioscience Stock at Premium
  • Zivo Bioscience to Deregister Securities, Cease Public Reporting; CFO and Director Resign
  • 10% Owner Mark Strome Increases Stake in Zivo Bioscience with $195K Stock Purchase
  • Director Alison Cornell Buys Nearly $100K in Zivo Bioscience Stock
  • CEO John Payne Reports Nearly $100K Open Market Stock Purchase

Financial Snapshot

Fiscal year ended December 31, 2024
Revenue
$157.22K
Net Income
-$13.38M
Diluted EPS
-$4.23
Op. Cash Flow
-$4.31M
Gross Profit
$48.95K
Operating Income
-$13.36M
Cash & Equivalents
$1.54M
Debt / Equity
0.00×
Net Margin
-85.13×
Shares Outstanding
3.62M sh
Source: 10-K · filed 2025-03-18 · accession 0001654954-25-002948
Browse all tickers starting with Z →
$3.67
52-week range · as of 2026-04-24 $1.1 – $22.15
Market cap
$14.27M
Volume
1.1K (0.2× avg)
3-mo avg 4.9K
Live data · 2026-06-12 20:08 UTC · After hours

show_chartPrice Chart

Loading chart...

feed ZIVO - Latest Insights

ZIVO
Apr 24, 2026, 6:16 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $3.67 info
Change: +$2.47 (+206%) info
Market Cap: $14.271M info
ZIVO
Mar 30, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $3.67 info
Change: -$2.83 (-44%) info
Market Cap: $14.271M info
ZIVO
Feb 17, 2026, 6:22 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $10.00
Real-time Price: $3.67 info
Change: -$6.33 (-63%) info
Market Cap: $14.271M info
ZIVO
Jan 28, 2026, 4:11 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $9.00
Real-time Price: $3.67 info
Change: -$5.33 (-59%) info
Market Cap: $14.271M info
ZIVO
Jan 28, 2026, 4:06 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $9.00
Real-time Price: $3.67 info
Change: -$5.33 (-59%) info
Market Cap: $14.271M info